Megan Sterchi Lammert to Serve on GLP-1 Litigation Panel at ABA Regional CLE Program

On Oct. 22, Baker Sterchi Member Megan Sterchi Lammert will serve as a panelist for “Weighing In: The State of the GLP-1 Docket” during the American Bar Association’s 2026 Products Liability & Life Sciences Regional CLE Program. The program will take place Oct. 21-22 at Chubb in Philadelphia.

The panel will examine litigation involving GLP-1 receptor agonists, a class of medications used to treat diabetes and obesity. Topics will include the status of multidistrict litigation, key rulings concerning causation and failure-to-warn claims and scientific issues underlying alleged injuries.

The two-day program, presented by the ABA Litigation Section’s Women in Products Liability and Pharmaceutical, Medical Devices & Biotech Litigation Subcommittees, will address recent legal developments, emerging technologies and litigation trends affecting product liability cases. Sessions will cover topics ranging from artificial intelligence and expert testimony to pharmaceutical and consumer product litigation.

Based in Baker Sterchi’s Kansas City office, Sterchi Lammert defends clients in personal injury, product liability and premises liability matters, including cases involving pharmaceutical and medical device companies. She serves as regional chair of ALFA International’s Product Liability & Complex Torts Practice Group and is licensed to practice in Missouri and Kansas.